GlassScriptPhysician profile
Anthony Joseph Gingo
NPI 1700878022
$4,001.80
in general payments reported to CMS, 2019-2025
31 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $445 · 2021: $809 · 2022: $972 · 2023: $491 · 2024: $319 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,015 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,014.79 |
| Education | $125.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,535.62 | 2019-2025 | |
| Avion Pharmaceuticals | $396.05 | 2020-2023 | Balcoltra |
| Pfizer INC. | $348.82 | 2019-2024 | |
| Astellas Pharma US INC | $219.14 | 2023-2025 | Veozah |
| Agile Therapeutics, INC. | $154.64 | 2021-2024 | Twirla |
| Mayne Pharma Commercial LLC | $154.63 | 2021-2025 | |
| Therapeuticsmd, INC. | $101.39 | 2019-2021 | |
| Millicent US INC | $100.78 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Currax Pharmaceuticals LLC | $93.32 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $75.54 | 2022 | |
| Sumitomo Pharma America, INC. | $73.00 | 2025 | Myfembree |
| Exeltis, USA INC. | $69.41 | 2023-2025 | Slynd |
| Organon LLC | $58.16 | 2022-2025 | Nexplanon |
| Myovant Sciences INC. | $55.66 | 2022 | |
| Sage Therapeutics, LLC | $52.69 | 2021-2025 | Zurzuvae |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $52.63 | 2019-2020 | |
| Hologic Sales and Service, LLC | $49.48 | 2019-2021 | |
| Roche Diagnostics Corporation | $45.80 | 2019 | |
| Evofem Biosciences, INC. | $45.57 | 2021-2022 | |
| Vivus LLC | $41.62 | 2019 | |
| Aspira Women'S Health INC | $41.23 | 2022-2024 | Ova1 |
| Amgen INC. | $37.64 | 2019-2021 | |
| Daiichi Sankyo INC. | $35.95 | 2019-2021 | |
| Alfasigma USA, INC. | $31.02 | 2020 | |
| Amag Pharmaceuticals, INC. | $30.96 | 2019 | |
| Exact Sciences Corporation | $27.48 | 2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $22.75 | 2019 | |
| Shield Therapeutics INC | $16.89 | 2024 | |
| Mission Pharmacal Company | $11.61 | 2020 | |
| Mylan Pharmaceuticals INC. | $11.33 | 2021 | |
| Minerva Surgical, INC | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Gingo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.